HD-OPM Archive
Topics › Blood vessels, circulation & endothelium

Rapamycin on stents blocks scar-tissue restenosis, not plaque; it failed in marmosets

Louis Nervegna · Dec 13, 2025 · ♥ 7 reactions · 0 comments · original Facebook post
Blood vessels, circulation & endotheliumHeart attack, stroke & proceduresAging & longevity
AI summary & key facts

Louis explains that rapamycin is used on drug-eluting stents because it inhibits vascular smooth muscle overproliferation (neointimal scar tissue), which is what usually causes restenosis, not because it prevents plaque. He distinguishes plaque from scar tissue and notes Adam Salmon's group found rapamycin did not inhibit plaque growth in marmosets.

Rapamycin is included in human heart stents mainly because it prevents the growth of scar tissue due to overproliferation of vascular smooth muscle cells. Not because it prevents growth of plaque in humans. It is a potent antifibrotic. Scar tissue is what usually causes rapid restenosis of heart stents, not plaque.

Plaque and scar tissue are different things. Plaque is a complex accumulation of lipids, inflammatory cells, and fibrous tissue that develops over a long period, while arterial scar tisue (neointimal hyperplasia) is a rapid, short-term healing response to vessel injury.

Rapamycin does NOT inhibit the growth of plaque in the arteries of marmosets (the shortest lived primate). This has been rigorously tested by Adam Salmon’s research group. It unfortunately does not work:

↪ Rapamycin did not slow atherosclerosis in marmosets, and why stents use it anyway

facebook.com/share/p/1BUAKN4d4M

Marmosets are much closer to humans than mice.

#rapamycinHD #stentsHD #marmosetsHD #adamsalmonHD #mtorHD #restenosisHD #vsmcHD

Research cited

← newer: VO2max as a causal longevity metric is doubtful; Mendelian rolder: Post about a possible aspirin anticancer mechanism with unav →